In Vitro Diagnostics (IVD) include reagents, instruments, and systems intended for use in the diagnosis of disease or other conditions, including the determination of the state of health, in order to treat or prevent disease. The reagents, instruments and systems are used in the collection, preparation, and examination of specimens taken from the human body. This includes Cardiac Disease, Hematological Disorders, Hormonal Disorders, Metabolic Disorder, Infectious Disease, IVD Analyzers, Oncology and Reproductive Health Diagnostics. Kirsten Rat Sarcoma Virus (KRAS) gene tests are carried out to detect gene mutations in patient tissue samples; the outcome of which may guide therapies to treat various cancers including Colorectal Cancer (CRC), certain lung cancers, and some leukemias. GlobalData uses proprietary data and analytics to provide a comprehensive report on the kras tests devices market, including market shares of different players within Israel. Buy the latest report here.
In 2023, GlobalData’s Market Model methodology determined that the leading player in the kras tests market in Israel was Qiagen followed by F. Hoffmann-La Roche and Biocartis Group.
CRC is classified based on the stage of the disease at diagnosis. CRC has been divided into localized, regional metastasis, and distant metastasis. Localized CRC is defined as cancer that has not yet metastasized. Regional metastasis refers to cancer that has spread to the lymph nodes near the colon or rectum. Distant metastasis refers to cancer that has spread to other organs of the body such as the lungs. There are two other widely used systems to classify CRC. The first groups CRC into stages -IV and the second use a lettering system (A-D). GlobalData considers stage -II & A-B as localized, stage III & stage C as regional metastasis, and stage IV & stage D as distant metastasis. The KRAS Tests includes Colorectal Cancer Stages of Diagnosis, KRAS Sanger Sequencing Tests; KRAS Nucleic Acid Amplification Tests (NAATs), and KRAS Other Tests comprises of In Situ Hybridisation (ISH) and Mass Array.
The value of the kras tests devices market within Israel was expected to be over $0.07m in 2023.
For the latest complete market share analysis of kras tests device market in Israel, buy the report here.
Data Insights
From
The gold standard of business intelligence.
Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.